studies

non squamous cell - mNSCLC - L1, atezolizumab based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpower-130 (all population), 2019 0.80 [0.65; 0.99] IMpower-130 (WT), 2019 0.79 [0.64; 0.98] IMpower-150 (ABCP vs BPC WT), 2018 0.78 [0.64; 0.96] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.76 [0.63; 0.92] IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.85 [0.71; 1.02] 0.80[0.73; 0.87]IMpower-130 (all population), 2019, IMpower-130 (WT), 2019, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 201850%3,700moderatenot evaluable progression or deaths (PFS)detailed resultsIMpower-130 (all population), 2019 0.65 [0.54; 0.78] IMpower-130 (WT), 2019 0.64 [0.54; 0.76] IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 0.51 [0.38; 0.68] IMpower-150 (ABCP vs BPC WT), 2018 0.62 [0.52; 0.74] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.61 [0.52; 0.72] IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.91 [0.78; 1.06] 0.66[0.56; 0.76]IMpower-130 (all population), 2019, IMpower-130 (WT), 2019, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018676%3,980moderatenot evaluable DORdetailed resultsIMpower-130 (WT), 2019 2.41 [1.27; 4.60] 2.41[1.27; 4.60]IMpower-130 (WT), 201910%292NAnot evaluable objective responses (ORR)detailed resultsIMpower-130 (WT), 2019 2.07 [1.48; 2.89] IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 1.96 [1.20; 3.19] IMpower-150 (ABCP vs BPC WT), 2018 1.88 [1.38; 2.55] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.95 [1.47; 2.58] IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 1.02 [0.77; 1.35] 1.70[1.28; 2.27]IMpower-130 (WT), 2019, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018574%3,231moderatenot evaluable AE (any grade)detailed resultsIMpower-130 (all population), 2019 2.05 [0.29; 14.63] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.49 [0.15; 1.65] 0.81[0.21; 3.04]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018232%1,492moderatenot evaluable AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.72 [1.19; 2.47] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.14 [0.86; 1.52] 1.38[0.93; 2.05]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018267%1,492moderatenot evaluable AE leading to death (grade 5)detailed resultsIMpower-130 (all population), 2019 0.94 [0.47; 1.87] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.10 [0.60; 2.03] 1.03[0.65; 1.62]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,492moderatenot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMpower-130 (all population), 2019 1.27 [0.88; 1.85] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.46 [1.07; 1.99] 1.38[1.09; 1.75]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,492moderatenot evaluable SAE (any grade)detailed resultsIMpower-130 (all population), 2019 1.69 [1.22; 2.32] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.40 [1.05; 1.87] 1.52[1.23; 1.89]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,492moderatenot evaluable STRAE (any grade)detailed resultsIMpower-130 (all population), 2019 2.09 [1.35; 3.24] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.43 [1.02; 2.00] 1.68[1.16; 2.43]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018245%1,492moderatenot evaluable TRAE (any grade)detailed resultsIMpower-130 (all population), 2019 2.00 [1.01; 3.95] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.81 [0.43; 1.53] 1.26[0.52; 3.06]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018272%1,492moderatenot evaluable TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.79 [1.28; 2.50] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.38 [1.04; 1.83] 1.55[1.20; 1.99]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018228%1,492moderatenot evaluable TRAE leading to death (grade 5)detailed resultsIMpower-130 (all population), 2019 3.97 [0.49; 31.97] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01] 1.49[0.64; 3.48]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201822%1,492moderatenot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.06; 16.09] 1.00[0.06; 16.09]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.49 [0.01; 24.77] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65] 0.70[0.04; 11.23]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,492moderatenot evaluable Anaemia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.62 [1.11; 2.36] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.05 [0.58; 1.89] 1.39[0.92; 2.09]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018233%1,492moderatenot evaluable Arthralgia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.75 [0.17; 3.37] 0.75[0.17; 3.37]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.48 [0.40; 5.52] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.45 [0.15; 1.30] 0.76[0.24; 2.44]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018248%1,492moderatenot evaluable Colitis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.53 [0.49; 13.10] 2.53[0.49; 13.10]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.03; 29.35] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65] 0.99[0.08; 12.92]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,492moderatenot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.86 [0.25; 2.95] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32] 1.41[0.34; 5.85]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018231%1,492moderatenot evaluable Diabetes TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65] 1.00[0.02; 50.65]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.03 [0.49; 2.14] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 5.64 [1.24; 25.63] 2.11[0.40; 10.96]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018275%1,492moderatenot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.49 [0.01; 24.77] 0.49[0.01; 24.77]IMpower-130 (all population), 201910%705NAnot evaluable Epistaxis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59] 8.09[0.43; 153.59]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.02 [0.53; 1.96] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.31 [0.57; 3.03] 1.12[0.67; 1.88]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,492moderatenot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.48 [0.85; 2.57] 1.48[0.85; 2.57]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59] 8.09[0.43; 153.59]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Hypertension TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.57; 1.78] 1.00[0.57; 1.78]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 2.01[0.07; 60.02]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 2.01[0.07; 60.02]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 2.01[0.07; 60.02]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32] 4.04[0.45; 36.32]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32] 4.04[0.45; 36.32]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.77 [0.51; 6.09] 1.77[0.51; 6.09]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.18; 22.26] 2.01[0.18; 22.26]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 2.01[0.07; 60.02]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.61 [0.52; 5.00] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.91 [0.80; 4.57] 1.80[0.90; 3.58]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,492moderatenot evaluable Nephritis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 2.01[0.07; 60.02]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.22 [0.86; 1.72] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.27 [0.83; 1.94] 1.24[0.95; 1.62]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,492moderatenot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.03 [0.18; 89.56] 4.03[0.18; 89.56]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.50 [0.02; 14.97] 0.50[0.02; 14.97]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01] 1.23[0.50; 3.01]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3.04 [0.61; 15.15] 3.04[0.61; 15.15]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Rash TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 10.14 [0.55; 186.27] 10.14[0.55; 186.27]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Sepsis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 2.01[0.07; 60.02]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32] 4.04[0.45; 36.32]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.52 [0.83; 2.79] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.94 [0.47; 1.89] 1.24[0.78; 1.97]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201823%1,492moderatenot evaluable Vomiting TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.48 [0.40; 5.52] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.21 [0.37; 3.99] 1.32[0.55; 3.21]IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,492moderatenot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.03; 29.35] 0.98[0.03; 29.35]IMpower-130 (all population), 201910%705NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.23 [0.24; 6.38] 1.23[0.24; 6.38]IMpower-130 (all population), 201910%705NAnot evaluable Agranulocytosis (AE grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.24 [0.01; 7.31] 0.24[0.01; 7.31]IMpower-130 (all population), 201910%705NAnot evaluable Alopecia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.49 [0.01; 24.77] 0.49[0.01; 24.77]IMpower-130 (all population), 201910%705NAnot evaluable Anaemia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.47 [1.03; 2.11] 1.47[1.03; 2.11]IMpower-130 (all population), 201910%705NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 7.97 [0.46; 139.30] 7.97[0.46; 139.30]IMpower-130 (all population), 201910%705NAnot evaluable Asthenia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.59 [0.58; 4.39] 1.59[0.58; 4.39]IMpower-130 (all population), 201910%705NAnot evaluable Back pain AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 3.97 [0.49; 31.97] 3.97[0.49; 31.97]IMpower-130 (all population), 201910%705NAnot evaluable Blood creatinine increased AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.97 [0.09; 43.77] 1.97[0.09; 43.77]IMpower-130 (all population), 201910%705NAnot evaluable Colitis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 2.96 [0.15; 59.25] 2.96[0.15; 59.25]IMpower-130 (all population), 201910%705NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 4.95 [0.27; 90.93] 4.95[0.27; 90.93]IMpower-130 (all population), 201910%705NAnot evaluable Cough AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 2.96 [0.15; 59.25] 2.96[0.15; 59.25]IMpower-130 (all population), 201910%705NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.33; 2.90] 0.98[0.33; 2.90]IMpower-130 (all population), 201910%705NAnot evaluable Diabetes mellitus AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.97 [0.09; 43.77] 1.97[0.09; 43.77]IMpower-130 (all population), 201910%705NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.87 [0.44; 1.70] 0.87[0.44; 1.70]IMpower-130 (all population), 201910%705NAnot evaluable Dizziness AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.49 [0.03; 7.86] 0.49[0.03; 7.86]IMpower-130 (all population), 201910%705NAnot evaluable Dry skin AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.24 [0.01; 7.31] 0.24[0.01; 7.31]IMpower-130 (all population), 201910%705NAnot evaluable Dysgeusia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.49 [0.01; 24.77] 0.49[0.01; 24.77]IMpower-130 (all population), 201910%705NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 5.61 [1.31; 24.06] 5.61[1.31; 24.06]IMpower-130 (all population), 201910%705NAnot evaluable Epistaxis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.49 [0.03; 7.86] 0.49[0.03; 7.86]IMpower-130 (all population), 201910%705NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.28 [0.68; 2.43] 1.28[0.68; 2.43]IMpower-130 (all population), 201910%705NAnot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.90 [0.33; 2.46] 0.90[0.33; 2.46]IMpower-130 (all population), 201910%705NAnot evaluable Gastritis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.97 [0.09; 43.77] 1.97[0.09; 43.77]IMpower-130 (all population), 201910%705NAnot evaluable Headache AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.03; 29.35] 0.98[0.03; 29.35]IMpower-130 (all population), 201910%705NAnot evaluable Hypertension AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.48 [0.30; 7.38] 1.48[0.30; 7.38]IMpower-130 (all population), 201910%705NAnot evaluable Hyperthyroidism AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.49 [0.03; 7.86] 0.49[0.03; 7.86]IMpower-130 (all population), 201910%705NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.97 [0.09; 43.77] 1.97[0.09; 43.77]IMpower-130 (all population), 201910%705NAnot evaluable Increase AST AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.24; 3.96] 0.98[0.24; 3.96]IMpower-130 (all population), 201910%705NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.73 [0.20; 2.62] 0.73[0.20; 2.62]IMpower-130 (all population), 201910%705NAnot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.03; 29.35] 0.98[0.03; 29.35]IMpower-130 (all population), 201910%705NAnot evaluable Leucopenia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.57 [0.66; 3.73] 1.57[0.66; 3.73]IMpower-130 (all population), 201910%705NAnot evaluable Myalgia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.03; 29.35] 0.98[0.03; 29.35]IMpower-130 (all population), 201910%705NAnot evaluable Nausea AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.59 [0.58; 4.39] 1.59[0.58; 4.39]IMpower-130 (all population), 201910%705NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.24 [0.88; 1.75] 1.24[0.88; 1.75]IMpower-130 (all population), 201910%705NAnot evaluable Pancytopenia (AE grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.49 [0.07; 3.49] 0.49[0.07; 3.49]IMpower-130 (all population), 201910%705NAnot evaluable Paraesthesia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.97 [0.09; 43.77] 1.97[0.09; 43.77]IMpower-130 (all population), 201910%705NAnot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.73 [0.12; 4.42] 0.73[0.12; 4.42]IMpower-130 (all population), 201910%705NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.73 [0.12; 4.42] 0.73[0.12; 4.42]IMpower-130 (all population), 201910%705NAnot evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.24; 3.96] 0.98[0.24; 3.96]IMpower-130 (all population), 201910%705NAnot evaluable Pneumonia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.40 [0.67; 2.93] 1.40[0.67; 2.93]IMpower-130 (all population), 201910%705NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.24 [0.01; 7.31] 0.24[0.01; 7.31]IMpower-130 (all population), 201910%705NAnot evaluable Pruritus AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.03; 29.35] 0.98[0.03; 29.35]IMpower-130 (all population), 201910%705NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.03; 29.35] 0.98[0.03; 29.35]IMpower-130 (all population), 201910%705NAnot evaluable Rash AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.09; 10.87] 0.98[0.09; 10.87]IMpower-130 (all population), 201910%705NAnot evaluable Rash maculopapular AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.03; 29.35] 0.98[0.03; 29.35]IMpower-130 (all population), 201910%705NAnot evaluable Sepsis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 6.95 [0.39; 123.09] 6.95[0.39; 123.09]IMpower-130 (all population), 201910%705NAnot evaluable Stomatitis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.24 [0.02; 2.70] 0.24[0.02; 2.70]IMpower-130 (all population), 201910%705NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.49 [0.83; 2.69] 1.49[0.83; 2.69]IMpower-130 (all population), 201910%705NAnot evaluable Vomiting AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.28 [0.45; 3.64] 1.28[0.45; 3.64]IMpower-130 (all population), 201910%705NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:48 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 307,165,163,176 - treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866